SCHEMBL6511253

SCHEMBL6511253

CCc1ccc(-c2nc(CO)c(C)o2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.60
RAB9A P51151 1/20 0.60
POLB P06746 4/20 0.52
MAPT P10636 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
NPSR1 Q6W5P4 2/20 0.50
PPARG P37231 1/20 0.49
PPARA Q07869 1/20 0.49
KMT2A Q03164 3/20 0.48
TP53 P04637 1/20 0.48
ALDH1A1 P00352 4/20 0.47
MEN1 O00255 2/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
KDR P35968 1/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TARBP2 Q15633 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365528 0.88 KDM4E (0.57) KDM4ERAB9APOLBMAPTSMN1; SMN2
SCHEMBL4925692 0.85 TP53 (0.52) KDM4ERAB9APOLBSMN1; SMN2KMT2A
SCHEMBL19697550 0.84 KDR (0.50) KDM4ERAB9APOLBMAPTPPARG
SCHEMBL4359109 0.84 KDM4E (0.56) KDM4ERAB9APOLBMAPTSMN1; SMN2
SCHEMBL5762006 0.82 HSD17B10 (0.56) KDM4EPOLBMAPTSMN1; SMN2PPARA
SCHEMBL5093853 0.82 TARBP2 (0.54) KDM4ERAB9APOLBSMN1; SMN2PPARG
SCHEMBL5096428 0.82 ALDH1A1 (0.51) KDM4ERAB9APOLBMAPTSMN1; SMN2
SCHEMBL4037331 0.81 KDM4E (0.69) KDM4ERAB9APPARGPPARATP53
SCHEMBL7906342 0.81 PPARG (0.47) KDM4ERAB9APPARGPPARAKMT2A
SCHEMBL5385072 0.80 KDM4E (0.50) KDM4ERAB9AMAPTPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170355686-A1 NOVEL OXAZOLE COMPOUNDS AS BETA CATENIN MODULATORS AND USES THEREOF UNIV NEW YORK (US) 2017-12-14 US disclosed
US-20170355686-A1 NOVEL OXAZOLE COMPOUNDS AS BETA CATENIN MODULATORS AND USES THEREOF UNIV NEW YORK (US) 2017-12-14 US disclosed
US-20170355686-A1 NOVEL OXAZOLE COMPOUNDS AS BETA CATENIN MODULATORS AND USES THEREOF UNIV NEW YORK (US) 2017-12-14 US disclosed
EP-3220915-A1 NOVEL OXAZOLE COMPOUNDS AS -CATENIN MODULATORS AND USES THEREOF New York University (US) 2017-09-27 EP disclosed
WO-2016081451-A1 NOVEL OXAZOLE COMPOUNDS AS β-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY (US) 2016-05-26 WO disclosed
WO-2016081451-A1 NOVEL OXAZOLE COMPOUNDS AS β-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY (US) 2016-05-26 WO disclosed
WO-2005040127-A1 NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME LG LIFE SCIENCES LTD. (KR) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355686-A1 NOVEL OXAZOLE COMPOUNDS AS BETA CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNND1, CTNNA1 KDM4E 3770/4885RAB9A 2586/4885POLB 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.